NorthWest Biotherapeutics Inc (NWBO)

[sukus]

Merck unfortunately has no experience with this kind of immunotherapy via FlaskWork and since FlaskWork is such a breakthrough technique, even CRL’s Cognate has no experience in it. But yes they can learn it as time permits. The only one who knows so well with years of experience already is the innovator or the founder himself or the Professor and probably his staffs.

BP I believe would probably demand to see the evidence first of this dramatic 10 times capacity improvement before writing big check.

Once they can see the result is equivalent to the old method, they I believe will be able to justify to their stakeholders as to why the bo is so expensive.

And I agree with you absolutely that BP with its strong muscle can move forward very rapidly once they can acquire this validated proof of concept much much faster than NWBO.